Promising Molecular Architectures for Two-Photon Probes in the Diagnosis of α-Synuclein Aggregates.
Stefania PorcuRiccardo CorpinoCarlo Maria CarbonaroPier Carlo RicciAttilio Vittorio VargiuAnna Laura SannaGiuseppe SforazziniDaniele ChiriuPublished in: Molecules (Basel, Switzerland) (2024)
The abnormal deposition of protein in the brain is the central factor in neurodegenerative disorders (NDs). These detrimental aggregates, stemming from the misfolding and subsequent irregular aggregation of α-synuclein protein, are primarily accountable for conditions such as Parkinson's disease, Alzheimer's disease, and dementia. Two-photon-excited (TPE) probes are a promising tool for the early-stage diagnosis of these pathologies as they provide accurate spatial resolution, minimal intrusion, and the ability for prolonged observation. To identify compounds with the potential to function as diagnostic probes using two-photon techniques, we explore three distinct categories of compounds: Hydroxyl azobenzene (AZO-OH); Dicyano-vinyl bithiophene (DCVBT); and Tetra-amino phthalocyanine (PcZnNH 2 ). The molecules were structurally and optically characterized using a multi-technique approach via UV-vis absorption, Raman spectroscopy, three-dimensional fluorescence mapping (PLE), time-resolved photoluminescence (TRPL), and pump and probe measurements. Furthermore, quantum chemical and molecular docking calculations were performed to provide insights into the photophysical properties of the compounds as well as to assess their affinity with the α-synuclein protein. This innovative approach seeks to enhance the accuracy of in vivo probing, contributing to early Parkinson's disease (PD) detection and ultimately allowing for targeted intervention strategies.
Keyphrases
- living cells
- single molecule
- molecular docking
- early stage
- small molecule
- raman spectroscopy
- molecular dynamics simulations
- fluorescent probe
- protein protein
- monte carlo
- high resolution
- randomized controlled trial
- energy transfer
- fluorescence imaging
- molecular dynamics
- mild cognitive impairment
- amino acid
- cognitive impairment
- multiple sclerosis
- squamous cell carcinoma
- cognitive decline
- drug delivery
- brain injury
- radiation therapy
- neoadjuvant chemotherapy
- resting state
- functional connectivity
- cerebral ischemia